Background Excessive exposure to light enhances the progression and severity of some human retinal degenerative diseases. While retinal microglia are likely to be important in neuron damage associated with these diseases, the relationship between photoreceptor damage and microglial activation remains poorly understood. Some recent studies have indicated that the chemokine fractalkine is involved in the pathogenesis of many neurodegenerative diseases. The present study was performed to investigate the cross-talk between injured photoreceptors and activated retinal microglia, focusing on the role of fractalkine and its receptor CX3CR1 in light-induced photoreceptor degeneration. Methodology/Principal Findings Both in vivo and in vitro experiments were involved in the research. In vivo, Sprague–Dawley rats were exposed to blue light for 24 hours. In vitro, the co-culture of primary retinal microglia and a photoreceptor cell line (661W cell) was exposed to blue light for five hours. Some cultures were pretreated by the addition of anti-CX3CR1 neutralizing antibody or recombinant fractalkine. Expression of fractalkine/CX3CR1 and inflammatory cytokines was detected by immunofluorescence, real-time PCR, Western immunoblot analysis, and ELISA assay. TUNEL method was used to detect cell apoptosis. In addition, chemotaxis assay was performed to evaluate the impact of soluble fractalkine on microglial migration. Our results showed that the expression of fractalkine that was significantly upregulated after exposure to light, located mainly at the photoreceptors. The extent of photoreceptor degeneration and microglial migration paralleled the increased level of fractalkine/CX3CR1. Compared with the control, the expression of inflammatory cytokines was significantly downregulated in the anti-CX3CR1 neutralizing antibody-treated group, and the number of photoreceptors was also well preserved. The addition of recombinant full-length fractalkine or soluble fractalkine resulted in fewer TUNEL-positive photoreceptors and an increased number of migratory microglia respectively. Conclusions/Significance These findings demonstrate that fractalkine/CX3CR1 interaction may play an important role in the photoreceptor-microglia cross-talk in light-induced photoreceptor degeneration.
References
[1]
Cruickshanks KJ, Klein R, Klein BE (1993) Sunlight and age-related macular degeneration: the Beaver Dam Eye Study. Arch Ophthalmol 111: 514–518.
[2]
Xu H, Chen M, Forrester JV (2009) Para-inflammation in the aging retina. Prog Retin Eye Res 28: 348–368.
[3]
Minghetti L (2005) Role of inflammation in neurodegenerative diseases. Curr Opin Neurol 18: 315–321.
[4]
Block M L, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57–69.
[5]
Streit WJ (2004) Microglia and Alzheimer's disease pathogenesis. J Neurosci Res 77: 1–8.
[6]
Kreutzberg GW (1996) Microglia: a sensor for pathological evets in the CNS. Trends Neurosci 19: 312–318.
[7]
Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, et al. (2005) ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 8: 752–758.
[8]
Hanisch UK, Kettenmann H (2007) Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10: 1387–1394.
[9]
Ni YQ, Xu GZ, Hu WZ, Shi L, Qin YW, et al. (2008) Neuroprotective effects of naloxone against light-induced photoreceptor degeneration through inhibiting retinal microglial activation. Invest Ophthalmol Vis Sci 49: 2589–2598.
[10]
Zhang C, Shen JK, Lam TT, Zeng HY, Chiang SK, et al. (2005) Activation of microglia and chemokines in light-induced retinal degeneration. Mol Vis 11: 887–895.
[11]
Yang LP, Zhu XA, Tso Mark OM (2007) A possible mechanism of microglia-photoreceptor crosstalk. Mol Vis 13: 231–232.
[12]
Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, et al. (2000) International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52: 145–176.
[13]
Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, et al. (1997) A new class of membrane-bound chemokine with a CX3C motif. Nature 385: 640–644.
[14]
Ransohoff RM (2009) Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity 31: 711–721.
[15]
Hughes PM, Botham MS, Frentzel S, Mir A, Perry VH (2002) Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia 37: 314–327.
[16]
Nishiyori A, Minami M, Ohtani Y, Takami S, Yamamoto J, et al. (1998) Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia? FEBS Lett 429: 167–172.
[17]
Garton , KJ , Gough PJ, Blobel CP, Murphy G, Greaves DR, et al. (2001) Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276: 37993–38001.
[18]
Hundhausen CD, Misztela TA, Berkhout N, Broadway P, Saftig K, et al. (2003) The disintegrin- like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102: 1186–1195.
[19]
Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, et al. (1998) Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA 95: 10896–10901.
[20]
Ceyhan GO, Deucker S, Demir IE, Erkan M, Schmelz M, et al. (2009) Neural fractalkine expression is closely linked to pain and pancreatic neuritis in human chronic pancreatitis. Lab Invest 89: 347–361.
[21]
Klosowska K, Volin MV, Huynh N, Chong KK, Halloran MM, et al. (2009) Fractalkine functions as a chemoattractant for osteoarthritis synovial fibroblasts and stimulates phosphorylation of mitogen-activated protein kinases and Akt. Clin Exp Immunol 156: 312–319.
[22]
Meucci O, Fatatis A, Simen AA, Miller RJ (2000) Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc Natl Acad Sci USA 97: 8075–8080.
[23]
Apostolakis S, Vlata Z, Vogiatzi K, Krambovitis E, Spandidos DA (2010) Angiotensin II up-regulates CX3CR1 expression in THP-1 monocytes: impact on vascular inflammation and atherogenesis. J Thromb Thrombolysis 29: 443–448.
[24]
Lesnik P, Haskell CA, Charo IF (2003) Decreased atherosclerosis in CX3CR1？/？ mice reveals a role for fractalkine in atherogenesis. J Clin Invest 111: 333–340.
[25]
Ross RJ, Zhou M, Shen D, Fariss RN, Ding XY, et al. (2008) Immunological protein expression profile in Ccl2/Cx3cr1 deficient mice with lesions similar to age-related macular degeneration. Exp Eye Res 86: 675–683.
[26]
Tuo JS, Bojanowski CM, Zhou M, Shen DF, Ross RJ, et al. (2007) Murine Ccl2/Cx3cr1 Deficiency Results in Retinal Lesions Mimicking Human Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci 48: 3827–3836.
[27]
Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, et al. (2006) Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 9: 917–924.
[28]
Milligan ED, Zapata V, Chacur M, Schoeniger D, Biedenkapp J, et al. (2004) Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur J Neurosci 20: 2294–2302.
[29]
Verge GM, Milligan ED, Maier SF, Watkins LR, Naevel GS, et al. (2004) Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur J Neurosci 20: 1150–1160.
[30]
Clark AK, Yip PK, Grist J, Gentry C, Staniland AA, et al. (2007) Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. PNAS 104: 10655–10660.
[31]
Sciume G, Soriani A, Piccoli M, Frati L, Santoni A, et al. (2010) CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1. neuro-oncology 12: 701–710.
[32]
Marchesi F, Locatelli M, Solinas G, Erreni M, Allavena P, et al. (2010) Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. J Neuroimmunol 224: 39–44.
[33]
Liu C, Luo DF, Streit WJ, Harrison JK (2008) CX3CL1 and CX3CR1 in the GL261 murine model of glioma: CX3CR1 deficiency does not impact tumor growth or infiltration of microglia and lymphocytes. J Neuroimmunol 198: 98–105.
[34]
Zujovic V, Benavides J, Vige X, Carter C, Taupin V (2000) Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia 29: 305–315.
[35]
Lauro C, Catalano M, Trettel F, Mainiero F, Ciotti MT, et al. (2006) The chemokine CX3CL1 reduces migration and increases adhesion of neurons with mechanisms dependent on the beta1integrin subunit. J Immunol 177: 7599–7606.
[36]
Liang KJ, Lee JE, Wang YQD, Ma WX, Fontainhas AM, et al. (2009) Regulation of Dynamic Behavior of Retinal Microglia by CX3CR1 Signaling. Invest Ophthalmol Vis Sci 50: 4444–4451.
[37]
Lauro C, Di Angelantonio S, Cipriani R, Sobrero F, Antonilli L, et al. (2008) Activity of adenosine receptors type 1 is required for CX3CL1-mediated neuroprotection and neuromodulation in hippocampal neurons. J Immunol 180: 7590–7596.
[38]
Raoul W, Keller N, Rodero M, Behar-Cohen F, Sennlaub F, et al. (2008) Role of the chemokine receptor CX3CR1 in the mobilization of phagocytic retinal microglial cells. J Neuroimmunol 198: 56–61.
[39]
Tarozzo G, Campanella M, Ghiani M, Bulfone A, Beltramo M (2002) Expression of fractalkine and its receptor, CX3CR1, in response to ischaemia-reperfusion brain injury in the rat. Eur J Neurosci 15: 1663–1668.
[40]
Soriano SG, Amaravadi LS, Wang YF, Zhou H, Yu GX, et al. (2002) Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol 125: 59–65.
[41]
Denes A, Ferenczi S, Halasz J, Kornyei Z, Kovacs KJ (2008) Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab 28: 1707–1721.
[42]
Liu ZQ, Condello C, Schain A, Harb R, Grutzendler J (2010) CX3CR1 in Microglia Regulates Brain Amyloid Deposition through Selective Protofibrillar Amyloid-beta Phagocytosis. J Neurosci 30: 17091–17101.
[43]
Fuhrmann M, Bittner T, Jung CK, Burgold S, Page RM, et al. (2010) Microglial CX3CR1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci 13: 411–413.
[44]
Sunnemark D, Eltayeb S, Nilsson M, Wallstrom E, Lassmann H, et al. (2005) CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. Neuroinflamm 2: 17.
[45]
Tan E, Ding XQ, Saadi A, Agarwal N, Naash MI, et al. (2004) Expression of cone-photoreceptor-specific antigens in a cell line derived from retinal tumors in transgenic mice. Invest Ophthalmol Vis Sci 45: 764–768.
[46]
Langmann T (2007) Microglia activation in retinal degeneration. J Leukoc Biol 81: 1345–1351.
[47]
Zujovic V, Benavides J, Vige X, Carter C, Taupin V (2000) Fractalkine modulates TNF alpha secretion and neurotoxicity induced by microglial activation. Glia 29: 305–315.
[48]
Limatola C, Lauro C, Catalano M, Ciotti MT, Bertollini C, et al. (2005) Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. J Neuroimmunol 166: 19–28.
[49]
Huang D, Han Y, Rani MR, Glabinski A, Trebst C, et al. (2000) Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation. Immunol Rev 177: 52–67.
[50]
Kremlev SG, Palmer C (2005) Interleukin-10 inhibits endotoxin-induced pro-inflammatory cytokines in microglial cell cultures. J Neuroimmunol 162: 71–80.
[51]
Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308: 1314–1318.
[52]
Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, et al. (2005) ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 8: 752–758.
[53]
Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308: 1314–1318.
[54]
Battista D, Ferrari CC, Gage FH, Pitossi FJ (2006) Neurogenic niche modulation by activated microglia: transforming growth factor beta increases neurogenesis in the adult dentate gyrus. Eur J Neurosci 23: 83–93.
Kempermann G, Neumann H (2003) Neuroscience-Microglia: the enemy within? Science 302: 1689–1690.
[57]
Minghetti L (2005) Role of inflammation in neurodegenerative diseases. Curr Opin Neurol 18: 315–321.
[58]
Ng TF, Streilein JW (2001) Light-induced migration of retinal microglia into the subretinal space. Invest Ophthalmol Vis Sci 42: 3301–3310.
[59]
Maciejewski-Lenoir D, Chen SZ, Feng LL, Maki R, Bacon KB (1999) Characterization of fractalkine in rat brain cells: Migratory and activation signals for CX3CR-1-expressing microglia. J Immunol 163: 1628–1635.
[60]
Chapman GA, Moores K, Harrison D, Campbell CA, Stewart BR, et al. (2000) Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J Neurosci 20: RC87.
[61]
Mizuno T, Kawanokuchi J, Numata K, Suzumura A (2003) Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res 979: 65–70.
[62]
Re DB, Przedborski S (2006) Fractalkine: moving from chemotaxis to neuroprotection. Nat Neurosci 9: 859–861.
[63]
Li L, Huang L, Sung SS, Vergis AL, Rosin DL, et al. (2008) The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int 74: 1526–1537.
[64]
Lu PR, Li LB, Liu GQ, van Rooijen N, Mukaida N, et al. (2009) Opposite Roles of CCR2 and CX3CR1 Macrophages in Alkali-induced Corneal Neovascularization. Cornea 28: 562–569.
[65]
Combadiere C, Feumi C, Raoul W, Keller N, Rodero M, et al. (2007) CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J Clin Invest 117: 2920–2928.
[66]
Dagkalis A, Wallace C, Hing B, Liversidge J, Crane IJ (2009) CX3CR1-deficiency is associated with increased severity of disease in experimental autoimmune uveitis. Immunology 28: 25–33.
